Search this website. You can use fund codes to locate specific funds

Tackling post-pandemic pharmaceutical challenges

A panel debate on the role of companies and investors

Last month we looked at post-pandemic pharmaceutical challenges as part of a panel session we hosted for the US Council of Institutional Investors (CII) virtual Spring 2021 conference.

Moderated by Katie Frame, our other engagers Dr Emma Berntman and Sarah Swartz were joined by Damiano de Felice, director of strategy at the Access to Medicine Foundation and Silas Holland, head of communications and external affairs at the AMR Action Fund.

The pandemic has highlighted the vulnerability of our healthcare systems and inequities in access to them. So we asked what can companies and investors do to mitigate these issues? What did we learn along the way in the race for the vaccine? And what has the pandemic shown in terms of links between the sustainability agenda and human health?

We take a global approach to engagement with companies so our panel applied an international lens to looking at these challenges, as well as wider issues such as antimicrobial resistance and equitable vaccine distribution. Inviting questions from the audience, make sure you catch up with this session to hear why companies and investors need to step up to tackle pharmaceutical challenges in a post-pandemic world.

Watch the recording in full below or click to jump to a section.

Opening remarks – 01:33

Stimulating greater investment into R&D – 26:58

Beyond Pharma – other actors tackling AMR – 33:32

Contributors of AMR – 42:06

Equitable vaccine distribution – 51:01

Closing remarks – 57:32

Related Insights

Shouting, but barely heard
Many frontline workers lack a voice and have been disproportionately impacted by the pandemic.
From farm to fork - key challenges for global food systems
Animal agriculture plays an outsized role when it comes to contributing to the climate crisis, as well as other environmental and social issues.
Flexible and vulnerable - the gig worker's dilemma
The pandemic has highlighted society’s dependency on the gig economy to provide essential services, and the exacerbated risks associated with precarious work.
Key issues for Japan’s 2021 voting season
We have stepped up our voting recommendations at Japanese companies, particularly on gender diversity and climate change.
Novartis case study
Novartis has increased its board gender diversity, appointed its first new auditor since 1940 and shown leadership on artificial intelligence.
How the pandemic is widening racial and ethnic inequities
The pandemic widened pre-existing racial and ethnic disparities and will continue to exacerbate those inequities unless more is done.

EOS Client Service and Business Development

Amy D’Eugenio,
Head of Client Service and Business Development, EOS